4.8 (265) In stock
Background Coronavirus disease 2019 (COVID-19) induces inflammation, autoantibody production, and thrombosis, which are common symptoms of autoimmune diseases, including rheumatoid arthritis (RA). However, the effect of COVID-19 on autoimmune disease is not yet fully understood. Methods This study was performed to investigate the effects of COVID-19 on the development and progression of RA using a collagen-induced arthritis (CIA) animal model. Human fibroblast-like synoviocytes (FLS) were transduced with lentivirus carrying the SARS-CoV-2 spike protein gene in vitro, and the levels of inflammatory cytokine and chemokine expression were measured. For in vivo experiments, CIA mice were injected with the gene encoding SARS-CoV-2 spike protein, and disease severity, levels of autoantibodies, thrombotic factors, and inflammatory cytokine and chemokine expression were assessed. In the in vitro experiments, the levels of inflammatory cytokine and chemokine expression were significantly increased by overexpression of SARS-CoV-2 spike protein in human FLS. Results The incidence and severity of RA in CIA mice were slightly increased by SARS-CoV-2 spike protein in vivo. In addition, the levels of autoantibodies and thrombotic factors, such as anti-CXC chemokine ligand 4 (CXCL4, also called PF4) antibodies and anti-phospholipid antibodies were significantly increased by SARS-CoV-2 spike protein. Furthermore, tissue destruction and inflammatory cytokine level in joint tissue were markedly increased in CIA mice by SARS-CoV-2 spike protein. Conclusions The results of the present study suggested that COVID-19 accelerates the development and progression of RA by increasing inflammation, autoantibody production, and thrombosis. Video Abstract
SARS-CoV-2 interactome ~ ViralZone
Signalling strength determines proapoptotic functions of STING
Frontiers Multifaceted role of SARS-CoV-2 structural proteins in
PDF] Immunotherapy of Autoimmune Diseases with Nonantibiotic
SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro
Signalling strength determines proapoptotic functions of STING
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
Frontiers Metformin Suppresses Monocyte Immunometabolic Activation by SARS -CoV-2 Spike Protein Subunit 1
Frontiers Self-DNA driven inflammation in COVID-19 and after
FOXP3 Monoclonal Antibody (FJK-16s), PE-eFluor™ 610 (61-5773-82)
Frontiers Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants
Production of SARS-CoV-2 Specific IFN-γ/IL-10 Co-producing CD4 T Cells from Convalescent Donors to Treat COVID-19: A Hypothesis
SARS-CoV-2 spike protein worsens rheumatoid arthritis in mice
SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: endotoxin contamination and lack of protein glycosylation as possible confounders
Frontiers Multifaceted role of SARS-CoV-2 structural proteins in
